top
Search terms
Results 1 - 10 of 37 - ordered by :
Pages: 1 2 3 4
Romanianjournal

E-mail: jill.pell@glasgow.ac.uk Global risk scores use individual level information on non-modifiable risk factors (such as age, sex, ethnicity and family history) and modifiable risk factors (such ...

Date : 08/07/2016
Ejhf

In 2009, the HEAAL investigators[1] reported that losartan 150 mg/day reduced the rate of death and admissions for heart failure with reduced ejection fraction (HFREF) compared with patients ...

European Journal of Heart Failure, Pitt, Bertram

Date : 01/12/2012 Item size : 72879 bytes
Ehjournal

In their trial, Cannon et al. report the superiority of the anti-PCSK9 monoclonal antibody (mAb) alirocumab (SAR236553/REGN727; s.c. 75 mg every 2 weeks) over ezetimibe (oral 10 mg once a day) in the ...

European Heart Journal, Editorial, Baris Gencer, François Mach

Date : 14/05/2015 Item size : 244342 bytes
Ehjournal

Communications from regulators such as the US Food and Drug Administration concerning potential side effects of statin therapy (particularly memory loss and the risk of diabetes) have created debate ...

European Heart Journal, Clinical update, Muh Geot Wong, Christoph Wanner, John Knight, Vlado Perkovic

Date : 14/11/2015
Ehjournal

Abstract Aims To compare the efficacy [low-density lipoprotein cholesterol (LDL-C) lowering] and safety of alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin 9, ...

European Heart Journal, Coronary artery disease, Christopher P. Cannon, Bertrand Cariou, Dirk Blom, James M. McKenney, Christelle Lorenzato, Robert Pordy, Umesh Chaudhari, Helen M. Colhoun

Date : 14/05/2015
Ehjournal

Abstract Aims On the basis of the JUPITER trial, European health authorities recently approved the use of rosuvastatin to reduce first major cardiovascular events among high' global risk primary ...

European Heart Journal, Koenig, Wolfgang, Ridker, Paul M

Date : 01/01/2011 Item size : 264590 bytes
Ehjournal

See page 1772 for the editorial comment on this article (doi:10.1093/eurheartj/eht136) Introduction Chronic kidney disease (CKD) is a major public health problem.1 Cardiovascular disease (CVD) ...

European Heart Journal, Hou, Wanyin, Lv, Jicheng, Perkovic, Vlado, Yang, Lihong, Zhao, Na, Jardine, Meg J., Cass, Alan, Zhang, Hong, Wang, Haiyan

Date : 21/06/2013
Ehjournal

Abstract Aims To compare the efficacy [low-density lipoprotein cholesterol (LDL-C) lowering] and safety of alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin 9, ...

European Heart Journal, Cannon, Christopher P., Cariou, Bertrand, Blom, Dirk, McKenney, James M., Lorenzato, Christelle, Pordy, Robert, Chaudhari, Umesh, Colhoun, Helen M.

Date : 14/05/2015 Item size : 271307 bytes
Ehjournal

In their trial, Cannon et al. report the superiority of the anti-PCSK9 monoclonal antibody (mAb) alirocumab (SAR236553/REGN727; s.c. 75 mg every 2 weeks) over ezetimibe (oral 10 mg once a day) in the ...

European Heart Journal, Gencer, Baris, Mach, François

Date : 14/05/2015 Item size : 176194 bytes
Ehjournal

Abstract The value of cholesterol lowering in preventing cardiovascular disease has now been established in patients with chronic kidney disease (CKD), who are intrinsically at high cardiovascular ...

European Heart Journal, Wong, Muh Geot, Wanner, Christoph, Knight, John, Perkovic, Vlado

Date : 14/11/2015